iBio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by iBio, Inc. on October 29, 2019, regarding events occurring on October 28 and October 29, 2019. The Company, incorporated in Delaware, operates under the ticker symbol IBIO on the NYSE American.
Key Financial Metrics and Capital Structure
The filing details the closing of a public offering that generated net proceeds of approximately $4.52 million after deducting underwriting discounts, commissions, and offering expenses. The offering consisted of:
- 2,450,000 shares of Common Stock.
- 4,510 shares of Series C Convertible Preferred Stock.
- 25,000,000 Series A Warrants (expiring on the second anniversary of issuance).
- 25,000,000 Series B Warrants (expiring on the seventh anniversary of issuance).
Each Common Stock share was sold with two warrants at a combined price of $0.20. Each Series C Preferred Share was sold with accompanying warrants at a combined price of $1,000. The filing does not provide specific data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in equity capital and the introduction of a new class of preferred stock. On October 28, 2019, the Company filed a Certificate of Designation with the Delaware Secretary of State to establish the rights and preferences of the Series C Convertible Preferred Stock. This filing became effective immediately upon submission.
Outlook, Risks, and Management Commentary
The Company engaged A.G.P./Alliance Global Partners as the sole underwriter for the offering. The filing does not contain forward-looking guidance, specific risk factors, or management commentary regarding future operational performance beyond the details of the capital raise. The proceeds are intended to support the Company's operations, though specific allocation is not detailed in this text.
Key Facts for Investor Verification
- Verify the total net proceeds of $4.52 million and the specific use of funds in subsequent filings.
- Review the full terms of the Series C Convertible Preferred Stock in the Certificate of Designation (Exhibit 3.1) to understand conversion rates and liquidation preferences.
- Confirm the dilution impact of the 2,450,000 new common shares and 50,000,000 total warrants issued.
- Check the underwriting agreement (Exhibit 1.1) for any lock-up periods or additional obligations.